PATENT CLAIM ANALYSIS

Application Number: 16130787
Application Type: Utility
Filing Date: 2018-09
Publication Date: 2019-01
Patent Classification: ["424", "085200"]

Abstract:
A novel approach to discover new drugs against MS and other autoimmune diseases is disclosed. The p40 family of cytokines has four members which include interleukin-12 (IL-12), the p40 monomer (p40), the p40 homodimer (p40 2 ), and the IL-23. To facilitate the studies on p40 2  and p40, neutralizing monoclonal antibodies (mAb) against mouse p40 2  and p40 were generated for the first time. MS and other autoimmune disease drug therapies including recombinant p40 and/or monoclonal antibody against p40 2  (mAb-p40 2  a3-1d) are disclosed.

Claim (Index 1):
A method for treating an autoimmune disease in a mammal, the method comprising:\n administering a combination of a recombinant p40 monomer and at least one monoclonal antibody against p40 2  homodimer to the mammal for treating an autoimmune disease in the mammal.

Metadata:
- Claim Count in Document: 1.0
- Percentile: 97.0
- Lexical Diversity: 1.71667
- Patent Class: 424.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['10840789', '11768582', '11234011', '11722312', '10514687']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.710443153202243
- 35 USC 102 Novelty (BERT): 0.4911474585722849
- Combined Prediction Score: 0.6885135837392473
- Mean Citation Score: 197.588962
- Max Citation Score: 221.48625
- Similarity Product: 160.22568724080918

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test